G. Michael

Potentiation of E‐4031‐induced torsade de pointes by HMR1556 or ATX‐II is not predicted by action potential short‐term variability or triangulation

J. Dempster, K. Kane, S. Coker, 2007, British journal of pharmacology.

Durability of treatment response after 1 year of therapy with seladelpar in patients with primary biliary cholangitis (PBC): final results of an international phase 2 study

S. Bergheanu, T. Hassanein, B. Bacon, 2020, Journal of Hepatology.

Adrenaline reveals the torsadogenic effect of combined blockade of potassium channels in anaesthetized guinea pigs

K. Kane, S. Coker, G Michael, 2008, British journal of pharmacology.

Treatment efficacy and safety of seladelpar, a selective peroxisome proliferator-activated receptor delta agonist, in primary biliary cholangitis patients: 12- and 26-week analysis from an ongoing international, randomized, dose raging phase 2 study

Robert L. Martin, D. Bernstein, S. Bergheanu, 2018 .